DUPILUMAB

Information current as at: 1 June 2026

PBAC meeting date: July 2026

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Dupixent®
Form and strength:: Injection 200 mg in 1.14 mL single dose pre-filled syringe

Injection 200 mg in 1.14 mL single dose pre-filled pen

Injection 300 mg in 2 mL single dose pre-filled syringe

Injection 300 mg in 2 mL single dose pre-filled pen
Submission sponsor:: SANOFI-AVENTIS AUSTRALIA PTY LTD
Condition/indication: (therapeutic use): Chronic severe atopic dermatitis
Listing requested:: To consider the sponsor's revised proposal for listing dupilumab for the treatment of chronic severe atopic dermatitis in children aged 6 months to 11 years who have had lesions for at least 6 months from the time of the initial diagnosis affecting either the whole body or the face/hands. This item was previously recommended by the PBAC at its March 2022 meeting.
Funding program:: PBS General Schedule
Request authority level:: Authority Required (Telephone/Online)
PBAC Submission type:: Change to existing listing (–)
Comment:: --
Other PBAC consideration:: --

Submission received for:: July 2026 PBAC meeting
Opportunity for consumer comment:: Open 25/03/2026 and close 20/05/2026 (see PBS Website)
3PBAC meeting:: Has not yet occurred
4PBAC outcome published:: Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Case ID

1224

Page last updated

31 May 2026

v.9.19